GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (STU:0Z2) » Definitions » Current Deferred Revenue

Alector (STU:0Z2) Current Deferred Revenue : €22.60 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alector Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Alector's current deferred revenue for the quarter that ended in Dec. 2024 was €22.60 Mil.

Alector Current Deferred Revenue Historical Data

The historical data trend for Alector's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alector Current Deferred Revenue Chart

Alector Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only 19.63 80.36 45.53 76.09 22.60

Alector Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.09 67.48 59.42 49.94 22.60

Alector Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Alector's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alector Business Description

Industry
Traded in Other Exchanges
Address
131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Alector Headlines

No Headlines